Announcements Trials
Browse Landscape

Phase

Phase 2 75Phase 1 60Phase 1/2 30Phase 3 18Phase EARLY_PHASE1 6Phase NA 5Phase 4 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Esophageal Squamous Cell Carcinoma 6Leukemia 5Esophageal Neoplasms 5Rectal Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oropharyngeal Neoplasms 2Oligodendroglioma 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, T-Cell 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Carcinoma 2Astrocytoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Temozolomide 8Lomustine 4vocimagene amiretrorepvec 2Radiation 2veliparib 1tinostamustine 1regorafenib 1carbon-11 acetate 1antisecretory factor 1Sunitinib 1Standard of Care 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1GDC-0084 1Flucytosine 1Etoposide 1Drug Therapy 1Disulfiram 1Dianhydrogalactitol 1DNA 1Copper 1Carbon-11 1Bevacizumab 1Alkylating Agents 1AZD1390 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Glioblastoma × Radiotherapy × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡